Airway Vista 2018

Invited Speakers

Scientific Program Invited Speakers

Stephanie London: National Institute of Environmental Health Sciences, USA

Alyn Morice: University of Hull, Castle Hill Hospital, Cottingham, UK

Le Thi Tuyet Lan: University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam

David Price: Observational and Pragmatic Research Institute, Singapore

Sundeep S Salvi: Chest Research Foundation, India

Graham Barr: Columbia University Medical Center, New York, USA

Brian Oliver: School of Life Sciences University of Technology Sydney, Australia

Namhee Kwon: Respiratory Global Franchise, GSK

Joon Beom Seo: Asan Medical Center, Seoul

You Sook Cho: Asan Medical Center, Seoul

Yeon-Mok Oh: Asan Medical Center, Seoul

Soo-Jong Hong: Asan Medical Center, Seoul

Eun Mi Chun: Ewha Womans university mokdong hospital

Se Hoon Kim: Seoul National University Bundang Hospital

Sei Won Lee: Asan Medical Center, Seoul

Chin Kook Rhee: Seoul St. Mary's Hospital

Joo Hee Kim: Sacred Heart Hospital Hallym University

Woo-Jung Song: Seoul National University Hospital, Seoul

Jae Seung Lee: Asan Medical Center, Seoul

Jae Chun Lee: Jeju National University Hospital

Jae Hyun Lee: Yonsei University, Severance Hospital

Jung-Kyu Lee: Seoul Metropolitan Governmental Seoul National University (SMG-SNU) Boramae Medical Center

Eunyoung Kim: Asan Medical Center, Seoul

Stephanie London: Respiratory Global Franchise, GSK; Dr. Stephanie Joan London is an Adjunct Professor of Epidemiology at University of North Carolina School of Public Health, and is a Senior Investigator of Epidemiology Branch at National Institute of Environmental Health Sciences. She also has been a councilor of National Institutes of Health. She is an expert in genetics and epigenetics of airway diseases. Her main research interests are genetic, epigenetic and environmental factors in respiratory and allergic illnesses.

Alyn Morice: University of Hull, Castle Hill Hospital, Cottingham, UK; Professor Morice qualified at Cambridge University and after House jobs in London undertook research (MD) into the pharmacology of asthma at St Mary’s Hospital. As Clinical Lecturer at Addenbrooke’s Hospital Professor Morice developed his interest in cough, demonstrating cough hypersensitivity caused by ACE inhibitors. In 1989 Professor Morice was appointed as Senior Lecturer in Sheffield developing a Pulmonary Vascular service and the first UK Cough Clinic. In 1998, Professor Morice was appointed to the Foundation Chair in Respiratory Medicine in Hull University (now part of Hull York Medical School). The Cough Clinic has become the largest centre within Europe with an international pattern of referral. Unique investigational strategies provide diagnosis and treatment advances which are incorporated into national and international guideline documents. Professor Morice has led the European Respiratory Society and British Thoracic Society Taskforces on Cough.

Le Thi Tuyet Lan: University of Medicine and Pharmacy at Ho Chi Minh City, Vietnam; Prof. Le Thi Tuyet Lan, MD., PhD. is a leading expert in the field of respirology in Viet Nam and worldwide. She graduated as a medical doctor from the University of Medicine and Pharmacy at Ho Chi Minh City (HCMC) in 1978, then completed her PhD degree in 1990 at the Academy of Medicine, Former Soviet Union. In 2000, she was recruited into the Fellowship of the American Association of Respiratory Care in the USA. She is now professor of the University of Medicine and Pharmacy at HCMC, Head of Respiratory Care Unit of the University Medical Center, Chairwoman of HCMC Society of Respirology and HCMC Society of Asthma, Allergy and Clinical Immunology. She was one of the first persons who established spirometry system in Viet Nam in 2000, translated into Vietnamese and disseminated GINA, GOLD and ARIA guidelines in Viet Nam. She has helped established 23 COPD and Asthma Care Units for commune health posts in Ho Chi Minh City and 90 COPD and Asthma Care Units for the hospitals in 26 provinces around Viet Nam. She has published 77 research articles in national and international medicine journals. She is now a member of Vietnamese Asthma Council, Vietnamese COPD Expert Panel, Asia Pacific COPD Advisory Board, Asia Pacific Respiratory Advisory Board. Moreover, she is one of the GINA assembly members, GOLD national leaders and a GARD initiator in Viet Nam. She has a big eager and enthusiasm in educating respiratory specialists and providing a professional medical system for managing patients with asthma, rhinitis as well as COPD in Viet Nam.

David Price: Observational and Pragmatic Research Institute, Singapore; Professor David Price is the founder and Managing Director of Observational and Pragmatic Research Institute (Singapore), an independent, research-driven organization established to cultivate initiatives, provide evidence and drive quality standards within the growing field of real-life, pragmatic and observational research. This dynamic organization delivers pragmatic clinical trials and real-life database research across multiple geographies, including territories in United States, Europe and the Asia-Pacific region, such as Singapore, South Korea, Taiwan, The Philippines, New Zealand, Australia, Japan and China. He is also Managing Director of Optimum Patient Care (Australia, Singapore, and UK), a science-based, social enterprise led by internationally recognised experts in all areas of respiratory medicine.

Professor Price founded the Respiratory Effectiveness Group (www.effectivenessevaluation.org), a not-for-profit, investigator-led initiative which uses an international collaborative approach to explore the optimum role of real-life research in informing clinical guidelines and improving patient care.

Professor Price is the Primary Care Respiratory Society Professor of Primary Care Respiratory Medicine at the University of Aberdeen, UK, and is a fellow of the European Respiratory Society (ERS). He is also a member of the World Health Organization (WHO) Allergic Rhinitis and its Impact on Asthma (ARIA) executive committee, the World Allergy Organization (WAO) Committee on Asthma, and the WAO Education Council.

Professor Price completed his medical degree at Cambridge University in 1984 and his general practitioner training in Norwich in 1989, where he later worked as a principal in general practice until 2000. He was chair of the research committee of the International Primary Care Respiratory Group (IPCRG) and was, until recently, the director for the Comprehensive Local Research Network in Norfolk and Suffolk and an honorary consultant at the Norfolk and Norwich Hospital and NHS Norfolk. He was previously Affiliate Associate Professor in the Department of General Practice at the University of Adelaide, Australia and held an Honorary Chair at the University of East Anglia, UK.

Professor Price is extensively involved in respiratory and allergy research; his areas of special interest are ‘real-life’ effectiveness and cost-effectiveness of interventions, clinical trial design, compliance, and patient attitudes to their disease. He is the author of more than 400 peer-reviewed publications and is responsible for approximately US$30 million in research and clinical development grants. He is currently Editor-in-Chief of the journal Pragmatic and Observational Research and member of the editorial board of several respiratory journals, including Lancet Respiratory Medicine.

Sundeep S Salvi: Chest Research Foundation, India; Dr Sundeep Salvi is the Director of Chest Research Foundation in Pune and a Visiting Faculty at the Imperial College, London, UK and the Johns Hopkins University, Baltimore, USA. After completing his training as a Pulmonologist from the University of Pune, he received a PhD from the University of Southampton in the UK where he researched on the harmful effects of diesel exhaust on the human lung, which is now a citation classic. He continued with his interest in air pollution and health after returning back to India at the Chest Research Foundation, a state-of-the art academic research institute that he helped found in 2002. He has worked on both ambient and household air pollution and has been an Advisory Board Member for the Committee on Air Pollution and Health initiated by the Ministry of Health and Family Welfare, Government of India. He has done some pioneering work on the levels of air pollution produced by the burning of biomass fuel during cooking practices, from the burning of mosquito coils, incense sticks and Diwali fire crackers. He has published over 200 papers in international peer reviewed journals and is the recipient of several national and international awards. He is an International Advisory Board Member for Lancet Respiratory Medicine and serves on the editorial board of several leading international journals.

Graham Barr: Respiratory Global Franchise, GSK; Dr. R. Graham Barr's research is primarily in respiratory epidemiology, relating to risk factors for asthma and chronic obstructive pulmonary disease (COPD). He has evaluated hormonal and analgesic risk factors for asthma and COPD in the Nurses' Health Study and is currently evaluating usage of over-the-counter analgesic drugs during asthma exacerbations. He is principal investigator (PI) of a longitudinal cohort study of fish oil intake and COPD among current and former smokers. He is co-PI of the Columbia Field Center of the MultiEthnic Study of Atherosclerosis, a 10-year prospective cohort study funded by NHLBI, PI of Mesa-Lung, a large study of endothelial function and lung function in that cohort, and PI at Columbia Mesa-Air, a 10-year prospective study on the health effects of air pollution funded by the EPA.

Brian Oliver: School of Life Sciences University of Technology Sydney, Australia; Associate Professor Oliver is a full time translational researcher, and leads the Molecular Pathogenesis group at the Woolcock Institute of Medical Research, and the University of Technology Sydney. He is best known for his innovative approach to understanding the pathophysiology of respiratory diseases. His scientific training began at the National Heart and Lung Institute, UK, with Prof Peter Barnes where he mastered the isolation and in-vitro culture of several types of lung cells. He then had further training in both molecular biology and then in virology at Prof Sebastian Johnston’s laboratory at Imperial College, UK before commencing his PhD at The University of Sydney supervised by Prof Judith Black.

Associate Professor Oliver is best known for his innovative approach to understanding the pathophysiology of respiratory diseases. For example, he was the first to show that cigarette smoke could induce airway fibrosis independent of inflammation, and how in-utero cigarette exposure affects subsequent development of lung disease. He has also been actively involved in drug development, including 3 patents. He has a number of publications which have clinical impact in both basic and clinical research. For example, he discovered important cellular mechanisms which increase the risk of post-viral secondary bacterial infections and his group developed an in-vitro model of rhinovirus-induced asthma exacerbations which is providing new insight into why β2-agonists may be ineffective during exacerbations. His clinical research has identified new serum based biomarkers for lymphangioleiomyomatosis (LAM), and through a series of publications spanning ten years has made significant discoveries in clinical respiratory virology. For example, he identified that exhaled breath contains viable respiratory viruses, and then refined the sampling methodology to provide sensitivity comparable to directly sampling airway secretions. His studies also examined virus flux, and how this relates to asthma symptoms and “back to school asthma” and more recently the virome.

Namhee Kwon: Respiratory Global Franchise, GSK; Namhee Kwon, a global medical director, is responsible for development and execution of medical strategies as well as evidence generation for mepolizumab. Her remit is across all regions in a preparation of a life cycle management of Nucala. She started her career in the pharmaceutical industry in 2006 as a medical adviser in respiratory and metabolic areas in GSK Korea. In 2008, she transitioned to lead the respiratory and immune-inflammation medical support for Asia Pacific countries, based in Singapore. In 2014, she started her global role as a medical director in the respiratory franchise based in London. Prior to joining GSK, she received her medical training and completed her Allergy and Clinical Immunology Fellowship in Samsung medical center. She holds an MD in Kyungbook National University, School of Medicine and a PhD degree with research on the molecular mechanism in asthma in Sungkyunkwan University, School of Medicine in Korea. Her key scientific interest is asthma and mechanisms on inflammatory diseases.